Search filters
Filters
Clear All

Phase

  • 183
  • 156
  • 2
  • 194
  • 1
  • 148
  • 17
  • 396
  • 1237
  • 588
  • 29
  • 49
  • 3
  • 1162
  • 1237
  • 6
  • 3
  • 1240

Found 1243 All Conditions trials

A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Safety and Immunogenicity Study of SARS-CoV-2 mRNA-1273 Vaccine in Adult Solid Organ Transplant Recipients and Healthy Controls

Safety and Immunogenicity Study of SARS-CoV-2 mRNA-1273 Vaccine in Adult Solid Organ Transplant Recipients and Healthy Controls

18 years - 99 years
Accepts healthy volunteer
All genders
Phase 3
The research study is being conducted to study the effectiveness of the mRNA-1273 study vaccine in people who have received a kidney or liver transplant. Healthy participants are being included in the study to compare the results from these participants to those who have had a kidney or liver transplant. …
Learn More
TEGSEDI Administration in Patients with Polyneuropathy of Hereditary Transthyretin-mediated Amyloidosis (hATTR-PN)

TEGSEDI Administration in Patients with Polyneuropathy of Hereditary Transthyretin-mediated Amyloidosis (hATTR-PN)

18 years - 99 years
All genders
Phase 4
TEGSEDI (also known as inotersen) is a medicine that has been approved in the United States, Europe and Canada to treat polyneuropathy (nerve damage) caused by hereditary transthyretin amyloidosis (hATTR-PN) in adults. hATTR-PN is a rare genetic disease that worsens over time if left untreated. This research study will examine …
Learn More
Prospective Open-Label Study Of Andexanet Alfa In Patients

Prospective Open-Label Study Of Andexanet Alfa In Patients

18 years - 85 years
All genders
Phase 2
Andexanet, a rationally designed, recombinant analog of endogenous human FXa, has been developed to rapidly and potently reverse FXa inhibition and restore physiologic coagulation. This study will examine the use of Andexanet inIn patients requiring urgent surgery who are being treated with a direct or indirect FXa inhibitor,
Learn More
Study to Evaluate the Efficacy and Safety of Nefecon Treatment in Patients With IgA Nephropathy Who Have Completed Study Nef-301

Study to Evaluate the Efficacy and Safety of Nefecon Treatment in Patients With IgA Nephropathy Who Have Completed Study Nef-301

18 years - 99 years
All genders
Interventional
This is a Phase 3b, multicenter, open-label extension (OLE) study to evaluate the efficacy and safety of Nefecon treatment in patients with IgAN who have completed the Phase 3 Study Nef 301 and continue to be treated with a stable dose of RAS inhibitor therapy (ACEIs and/or ARBs). Patients who …
Learn More
Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

18 years - 65 years
All genders
Phase 3
Interventional
This is a multi-center Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called CTP-543) in adults (18 years and older) who have 50% or greater scalp hair loss. The study is placebo-controlled, meaning that some patients entering the study will not receive active study …
Learn More
Patients Who Have Completed a Previous Oncology Study With Olaparib (ROSY-O)

Patients Who Have Completed a Previous Oncology Study With Olaparib (ROSY-O)

18 years - 99 years
Female
Prior participants of ROSY-O study
Learn More
Implementation mapping to increase the use of evidence-based interventions in the HIV continuum of care

Implementation mapping to increase the use of evidence-based interventions in the HIV continuum of care

18 years - 99 years
All genders
Observational
We will conduct about 24 qualitative interviews over the phone with clinicians, administrators, and policy-makers within a network of 23 Ryan White-funded medical clinics in the Philadelphia area within the PDPH network that deliver HIV prevention and intervention services. We will also develop a multi-level menu of implementation strategies using …
Learn More
Size and Decay of HIV-1 Reservoirs in Tissues and Cerebrospinal Fluid in Participants on Long-Term Antiretroviral Therapy

Size and Decay of HIV-1 Reservoirs in Tissues and Cerebrospinal Fluid in Participants on Long-Term Antiretroviral Therapy

18 years - 99 years
All genders
The purpose of this study is to look at where human immunodeficiency virus (HIV) might be “hiding” when standard lab tests show that HIV levels in the blood are very low.
Learn More
Studying symptomatic Transthyretin Amyloid Cardiomyopathy for those who Completed the Phase 3 ATTRibute-CM Trial (AG10-301)

Studying symptomatic Transthyretin Amyloid Cardiomyopathy for those who Completed the Phase 3 ATTRibute-CM Trial (AG10-301)

18 years - 99 years
All genders
Phase 3
This open-label study is designed to evaluate the long-term safety and tolerability of acoramidis in participants with ATTR-CM, administered on a background of stable heart failure therapy. This study follows the randomized, double-blind, placebo-controlled Study AG10-301 which was designed to examine safety and efficacy in this same population.
Learn More
Integrating Clinical Trials and Real-World Endpoints Data (ICAREdata) Capture and Standardization Companion Study

Integrating Clinical Trials and Real-World Endpoints Data (ICAREdata) Capture and Standardization Companion Study

18 years - 99 years
All genders
Observational
The purpose of this study is to understand how we might better collect health information that tells us how subjects study treatment for their cancer is working, and how their overall health is changing over time. This is a companion study to protocol A071701.
Learn More
1041 - 1050 of 1243